Sarah A. Edwards

Sarah A. Edwards

Auto-generated profile, based on publicly available information

Sarah A. Edwards

Brant County Health Unit

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2011 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
VKVictoria A. Kirsh
Victoria A. Kirsh
ACAnna M. Chiarelli
Anna M. Chiarelli
SESarah A. Edwards
Sarah A. Edwards
FOFrances P. O’malley
Frances P. O’malley
RSRene S. Shumak
Rene S. Shumak
NBNorman F. Boyd
Norman F. Boyd
Background Few studies have compared the prognostic value of tumor characteristics by type of breast cancer diagnosed in the interval between mammographic screenings with screen-detected breast cancers. Methods We conducted a case–case study within the cohort of women (n = 431 480) in the Ontario Breast Screening Program who were aged 50 years and older and were screened between January 1, 1994, and December 31, 2002. Interval cancers, defined as breast cancers diagnosed within 24 months after a negative screening mammogram, were designated as true interval cancers (n = 288) or missed interval cancers (n = 87) if they were not identified at the time of screening but were identified in retrospect. Screen-detected breast cancers (n = 450) were selected to match interval cancers. Tumors were evaluated for stage, grade, mitotic index, histology, and expression of hormone receptors and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by conditional logistic regression. Results Both true and missed interval cancers were of higher stage and grade than matched screen-detected breast cancers. However, true interval cancers had a higher mitotic index (OR = 3.13, 95% CI = 1.81 to 5.42), a higher percentage of nonductal histology (OR = 1.94, 95% CI = 1.05 to 3.59), and were more likely to be both estrogen receptor–negative (OR = 2.09, 95% CI = 1.32 to 3.30) and progesterone receptor–negative (OR = 2.49, 95% CI = 1.68 to 3.70) compared with matched screen-detected tumors. Conclusions In this study, interval cancers were of higher stage and grade compared with screen-detected cancers. True interval cancers were more likely to have additional adverse prognostic features of estrogen and progesterone receptor negativity and nonductal morphology. The findings suggest a need for more sensitive screening modalities to detect true interval breast cancers and different approaches for early detection of fast-growing tumors.

1 March 2014 in Addictive Behaviors
Verified
Journal Article
Closed access
SESarah A. Edwards
Sarah A. Edwards
SBSusan J. Bondy
Susan J. Bondy
RCRussell C. Callaghan
Russell C. Callaghan
RMRobert E. Mann
Robert E. Mann

1 September 2013 in Radiology
Verified
Journal Article
Closed access
ACAnna M. Chiarelli
Anna M. Chiarelli
SESarah A. Edwards
Sarah A. Edwards
MPMaegan V. Prummel
Maegan V. Prummel
DMDerek Muradali
Derek Muradali
VMVicky Majpruz
Vicky Majpruz
MYMartin J. Yaffe
Martin J. Yaffe
To evaluate the performance of digital direct radiography (DR) and computed radiography (CR) compared with that of screen-film mammography (SFM) in large concurrent cohorts. This study was approved by the University of Toronto Research Ethics Board and did not require informed consent. Concurrent cohorts of women aged 50-74 years screened with DR (n = 220 520), CR (n = 64 210), or SFM (n = 403 688) between 2008 and 2009 were identified and followed for 12 months. Performance was compared between cohorts, with SFM as the referent cohort. Associations were examined by using mixed-effect logistic regression. The cancer detection rate was similar for DR (4.9 per 1000; 95% confidence interval [CI]: 4.7, 5.2) and SFM (4.8 per 1000; 95% CI: 4.7, 5.0); however, the rate was significantly lower for CR (3.4 per 1000; 95% CI: 3.0, 3.9) (odds ratio, 0.79; 95% CI: 0.68, 0.93). Recall rates were higher for DR (7.7%; 95% CI: 7.6%, 7.8%) and lower for CR (6.6%; 95% CI: 6.5%, 6.7%) than for SFM (7.4%; 95% CI: 7.3%, 7.5%). Positive predictive value was lower for CR (5.2%; 95% CI: 4.7%, 5.8%) than for SFM (6.6%; 95% CI: 6.4%, 6.8%); however, the adjusted odds were not significant. Although DR is equivalent to SFM for breast screening among women aged 50-74 years, the cancer detection rate was lower for CR. Screening programs should monitor the performance of CR separately and may consider informing women of the potentially lower cancer detection rates.

29 October 2011 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
SKSeija K. Kromm
Seija K. Kromm
JBJennifer Bethell
Jennifer Bethell
FKFerne Kraglund
Ferne Kraglund
SESarah A. Edwards
Sarah A. Edwards
ALAudrey Laporte
Audrey Laporte
WUWendy J. Ungar
Wendy J. Ungar

1 July 2017 in Canadian Journal of Public Health
Verified
Journal Article
Closed access
PDF file
HBHilary K. Brown
Hilary K. Brown
MMMelissa Mueller
Melissa Mueller
SESarah Edwards
Sarah Edwards
CMCatriona Mill
Catriona Mill
JEJoanne Enders
Joanne Enders
CDCindy-Lee Dennis
Cindy-Lee Dennis

1 November 2012 in European Journal Of Cancer Prevention
Verified
Journal Article
Closed access
ACAnna M. Chiarelli
Anna M. Chiarelli
SESarah A. Edwards
Sarah A. Edwards
ASAmanda J. Sheppard
Amanda J. Sheppard
LMLucia Mirea
Lucia Mirea
NCNelson Chong
Nelson Chong
FOFrances P. O'MAlley
Frances P. O'MAlley
Most studies reporting more favourable biological features of screen-detected breast cancers compared with symptomatic or interval cancers include initial or prevalent screens and therefore may not indicate the real benefit of screening on breast cancer mortality. We conducted case–case comparisons within a cohort of eligible women (N=771 715) who were aged 50–69 between 1 January 1995 and 31 December 2003. A randomly selected sample of breast cancers (N=1848) diagnosed among these women were compared by detection method. Tumour characteristics of interval cancers (N=362) diagnosed after 6–24 months of a negative screen or symptomatic breast cancers (N=491) were compared with subsequent screen-detected breast cancers diagnosed within 6 months of a positive screen (N=995) using polytomous logistic regression. Tumours were evaluated for clinical presentation, histology and expression of hormone receptors. Women with symptomatic detected [odds ratio (OR)=7.48, 95% confidence interval (CI)=5.38–10.38] and interval cancers (OR=2.20, 95% CI=1.56–3.10) were more often diagnosed at stage III–IV versus I than women with rescreen-detected cancers. After adjusting for tumour size, women with symptomatic cancers had tumours of higher grade (OR=1.50, 95% CI=1.05–2.15) and mitotic score (OR=1.69, 95% CI=1.15–2.49) and women with interval cancers had tumours of higher mitotic score (OR=1.52, 95% CI=1.01–2.28) compared with women diagnosed at screening. Subsequent screen-detected cancers are not only detected at an earlier stage but are also less aggressive, leading to a better prognosis. As long-term mortality reduction for breast screening may depend on subsequent screens, our study indicates that mammography screening can be effective in women aged 50–69.